Sterol regulatory element-binding protein 1 is required for ovarian tumor growth

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1346-1354

  Nie, Long Yun ^a   Lu, Qing Tao ^b   Li, Wei Hua ^a   Yang, Ning ^a   Dongol, Samina ^a   Zhang, Xin ^a   Jiang, Jie ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cell growth; Lipogenesis; Ovarian cancer; Sterol regulatory enzyme binding protein 1; Tumorigenesis

Indexed keywords

SHORT HAIRPIN RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BENIGN TUMOR; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADENOCARCINOMA, MUCINOUS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880621589     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2575     Document Type: Article

References (31)

1. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
2. Medes G, Thomas A and Weinhouse S: Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 13: 27-29, 1953.
3. Horton JD: Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans 30: 1091-1095, 2002.
4. Wang X, Sato R, Brown MS, Hua X and Goldstein JL: SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77: 53-62, 1994.
5. Horton JD and Shimomura I: Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 10: 143-150, 1999.
6. Brown MS and Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340, 1997.
7. Osborne TF: Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem 275: 32379-32382, 2000.
8. Edwards PA, Tabor D, Kast HR and Venkateswaran A: Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 1529: 103-113, 2000.
9. Yang YA, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW and Pizer ES: Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282: 132-137, 2003.
10. Li JN, Mahmoud MA, Han WF, Ripple M and Pizer ES: Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res 261: 159-165, 2000.
11. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W and Verhoeven G: Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92: 273-279, 2004.
12. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F and Evert M: Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140: 1071-1083, 2011.
13. Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z, Weifang D and Yongliang G: Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 18: 233-239, 1999.
14. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T and Kaneko S: Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 50: 100-110, 2009.
15. Swinnen JV, Brusselmans K and Verhoeven G: Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9: 358-365, 2006.
16. Mukherjee A, Wu J, Barbour S and Fang X: Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. J Biol Chem 287: 24990-25000, 2012.
17. Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, Bavi P and Al-Kuraya KS: Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and its inhibition potentiates cisplatin-induced apoptosis. Mol Med 17: 635-645, 2011.
18. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777, 2007.
19. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL and Schulze A: SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8: 224-236, 2008.
20. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998, 2003.
21. Krycer JR, Sharpe LJ, Luu W and Brown AJ: The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab 21: 268-276, 2010.
22. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K and Ishikawa Y: ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 68: 8547-8554, 2008.
23. Zu XY, Zhang QH, Liu JH, Cao RX, Zhong J, Yi GH, Quan ZH and Pizzorno G: ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat Anticancer Drug Discov 7: 154-167, 2012.
24. Luo DX, Tong DJ, Rajput S, Wang C, Liao DF, Cao D and Maser E: Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential. Recent Pat Anticancer Drug Discov 7: 168-184, 2012.
25. Wang C, Rajput S, Watabe K, Liao DF and Cao D: Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci 2: 515-526, 2010.
26. Tong L and Harwood HJ Jr: Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem 99: 1476-1488, 2006.
27. Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM, Wong TW and Rupnow BA: Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res 9: 1551-1561, 2011.
28. Igal RA: Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis 31: 1509-1515, 2010.
29. Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avances C, Allory Y, de la Taille A, Culine S, Blancou H, Cristol JP, Michel F, Sardet C and Fajas L: Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 9: 1740-1754, 2010.
30. Liu H, Liu JY, Wu X and Zhang JT: Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 1: 69-89, 2010.
31. Mashima T, Seimiya H and Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 100: 1369-1372, 2009.